宣泰医药产品拟中选集采 股东计划减持不超过2%股份

Group 1 - The core viewpoint of the news is that Xuantai Pharmaceutical's product, Ursodeoxycholic Acid Capsules, is expected to be selected for the national centralized procurement, which could lead to an expansion in sales scale and an increase in market share if contracts are signed and implemented [1] - The major shareholder, Finer Pharma Inc., plans to reduce its holdings by up to 9.0668 million shares, accounting for 2% of the total share capital, due to personal financial needs, with the reduction period set from March 11 to June 10, 2026 [1] Group 2 - In the recent stock performance, Xuantai Pharmaceutical's share price has decreased by 1.16% over the last 7 trading days, with a high of 10.55 yuan and a low of 10.14 yuan, resulting in a volatility of 3.95% [2] - As of February 13, the latest share price is 10.25 yuan, reflecting a daily decline of 0.19%, with a turnover rate of 0.00% [2] - On February 13, the net inflow of main funds was 0 yuan, indicating that trading was primarily driven by retail investors [2]